| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9327456 | Gynecologic Oncology | 2005 | 8 Pages |
Abstract
Histologic grade 3 tumor and lymphovascular invasion were the cogent predictors of vaginal relapse in our population. The cost and morbidity of vaginal brachytherapy should be balanced against the potential risk of vaginal relapse in this group of patients.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Andrea Mariani, Sean C. Dowdy, Gary L. Keeney, Michael G. Haddock, Timothy G. Lesnick, Karl C. Podratz,